nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PLA2G4A—Epirubicin—liver cancer	0.634	0.948	CbGbCtD
Orlistat—CYP3A4—Sorafenib—liver cancer	0.0218	0.0325	CbGbCtD
Orlistat—CYP3A4—Doxorubicin—liver cancer	0.0132	0.0197	CbGbCtD
Orlistat—Ethanolamine Oleate—CYP2E1—liver cancer	0.00169	1	CrCbGaD
Orlistat—Bullous eruption—Epirubicin—liver cancer	0.00159	0.0126	CcSEcCtD
Orlistat—Rash papular—Doxorubicin—liver cancer	0.00157	0.0124	CcSEcCtD
Orlistat—Neoplasm—Sorafenib—liver cancer	0.00154	0.0122	CcSEcCtD
Orlistat—Bullous eruption—Doxorubicin—liver cancer	0.00148	0.0117	CcSEcCtD
Orlistat—Eczema—Sorafenib—liver cancer	0.00138	0.0109	CcSEcCtD
Orlistat—Hepatic failure—Sorafenib—liver cancer	0.00138	0.0109	CcSEcCtD
Orlistat—Proctalgia—Epirubicin—liver cancer	0.00134	0.0106	CcSEcCtD
Orlistat—Proctalgia—Doxorubicin—liver cancer	0.00124	0.00982	CcSEcCtD
Orlistat—Anorectal discomfort—Epirubicin—liver cancer	0.00115	0.0091	CcSEcCtD
Orlistat—Dry skin—Sorafenib—liver cancer	0.00113	0.00896	CcSEcCtD
Orlistat—Abdominal pain upper—Sorafenib—liver cancer	0.00113	0.00893	CcSEcCtD
Orlistat—Hypokalaemia—Sorafenib—liver cancer	0.00113	0.0089	CcSEcCtD
Orlistat—Breast disorder—Sorafenib—liver cancer	0.00112	0.00883	CcSEcCtD
Orlistat—Gastritis—Sorafenib—liver cancer	0.0011	0.00865	CcSEcCtD
Orlistat—Anorectal discomfort—Doxorubicin—liver cancer	0.00107	0.00842	CcSEcCtD
Orlistat—Pancreatitis—Sorafenib—liver cancer	0.00105	0.00828	CcSEcCtD
Orlistat—Abdominal discomfort—Sorafenib—liver cancer	0.00103	0.0081	CcSEcCtD
Orlistat—Nail disorder—Epirubicin—liver cancer	0.000972	0.00767	CcSEcCtD
Orlistat—Infestation NOS—Sorafenib—liver cancer	0.000954	0.00753	CcSEcCtD
Orlistat—Infestation—Sorafenib—liver cancer	0.000954	0.00753	CcSEcCtD
Orlistat—Renal failure—Sorafenib—liver cancer	0.000938	0.00741	CcSEcCtD
Orlistat—Neuropathy peripheral—Sorafenib—liver cancer	0.000935	0.00738	CcSEcCtD
Orlistat—Hepatobiliary disease—Sorafenib—liver cancer	0.000902	0.00712	CcSEcCtD
Orlistat—Nail disorder—Doxorubicin—liver cancer	0.000899	0.0071	CcSEcCtD
Orlistat—Haemoglobin—Sorafenib—liver cancer	0.000861	0.0068	CcSEcCtD
Orlistat—Haemorrhage—Sorafenib—liver cancer	0.000856	0.00676	CcSEcCtD
Orlistat—Urinary tract disorder—Sorafenib—liver cancer	0.000846	0.00668	CcSEcCtD
Orlistat—Urethral disorder—Sorafenib—liver cancer	0.000839	0.00663	CcSEcCtD
Orlistat—Immune system disorder—Sorafenib—liver cancer	0.000773	0.00611	CcSEcCtD
Orlistat—Mediastinal disorder—Sorafenib—liver cancer	0.000772	0.00609	CcSEcCtD
Orlistat—Alopecia—Sorafenib—liver cancer	0.000757	0.00598	CcSEcCtD
Orlistat—Blood disorder—Epirubicin—liver cancer	0.000755	0.00596	CcSEcCtD
Orlistat—Mental disorder—Sorafenib—liver cancer	0.00075	0.00592	CcSEcCtD
Orlistat—Malnutrition—Sorafenib—liver cancer	0.000745	0.00589	CcSEcCtD
Orlistat—Dysgeusia—Sorafenib—liver cancer	0.00073	0.00577	CcSEcCtD
Orlistat—Cardiovascular disorder—Epirubicin—liver cancer	0.000717	0.00566	CcSEcCtD
Orlistat—Amenorrhoea—Epirubicin—liver cancer	0.000717	0.00566	CcSEcCtD
Orlistat—Muscle spasms—Sorafenib—liver cancer	0.000717	0.00566	CcSEcCtD
Orlistat—Blood disorder—Doxorubicin—liver cancer	0.000698	0.00551	CcSEcCtD
Orlistat—Rectal haemorrhage—Epirubicin—liver cancer	0.000698	0.00551	CcSEcCtD
Orlistat—Arthropathy—Epirubicin—liver cancer	0.000693	0.00547	CcSEcCtD
Orlistat—Angioedema—Sorafenib—liver cancer	0.000681	0.00538	CcSEcCtD
Orlistat—Cardiovascular disorder—Doxorubicin—liver cancer	0.000664	0.00524	CcSEcCtD
Orlistat—Amenorrhoea—Doxorubicin—liver cancer	0.000664	0.00524	CcSEcCtD
Orlistat—Cough—Sorafenib—liver cancer	0.00065	0.00514	CcSEcCtD
Orlistat—Rectal haemorrhage—Doxorubicin—liver cancer	0.000646	0.0051	CcSEcCtD
Orlistat—Arthropathy—Doxorubicin—liver cancer	0.000641	0.00506	CcSEcCtD
Orlistat—Myalgia—Sorafenib—liver cancer	0.000635	0.00501	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00063	0.00498	CcSEcCtD
Orlistat—Vaginal inflammation—Epirubicin—liver cancer	0.00063	0.00498	CcSEcCtD
Orlistat—Dry mouth—Sorafenib—liver cancer	0.000621	0.0049	CcSEcCtD
Orlistat—Eructation—Epirubicin—liver cancer	0.000619	0.00489	CcSEcCtD
Orlistat—Anaphylactic shock—Sorafenib—liver cancer	0.000608	0.0048	CcSEcCtD
Orlistat—Infection—Sorafenib—liver cancer	0.000604	0.00477	CcSEcCtD
Orlistat—Nervous system disorder—Sorafenib—liver cancer	0.000597	0.00471	CcSEcCtD
Orlistat—Vaginal infection—Epirubicin—liver cancer	0.000595	0.0047	CcSEcCtD
Orlistat—Skin disorder—Sorafenib—liver cancer	0.000591	0.00467	CcSEcCtD
Orlistat—Vaginal inflammation—Doxorubicin—liver cancer	0.000583	0.00461	CcSEcCtD
Orlistat—Cramps of lower extremities—Epirubicin—liver cancer	0.000579	0.00457	CcSEcCtD
Orlistat—Eructation—Doxorubicin—liver cancer	0.000573	0.00452	CcSEcCtD
Orlistat—Neoplasm—Epirubicin—liver cancer	0.00057	0.0045	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000554	0.00438	CcSEcCtD
Orlistat—Vaginal infection—Doxorubicin—liver cancer	0.000551	0.00435	CcSEcCtD
Orlistat—Cramps of lower extremities—Doxorubicin—liver cancer	0.000536	0.00423	CcSEcCtD
Orlistat—Dyspepsia—Sorafenib—liver cancer	0.000536	0.00423	CcSEcCtD
Orlistat—Decreased appetite—Sorafenib—liver cancer	0.000529	0.00418	CcSEcCtD
Orlistat—Neoplasm—Doxorubicin—liver cancer	0.000527	0.00416	CcSEcCtD
Orlistat—Diabetes mellitus—Epirubicin—liver cancer	0.000526	0.00415	CcSEcCtD
Orlistat—Gastrointestinal disorder—Sorafenib—liver cancer	0.000525	0.00415	CcSEcCtD
Orlistat—Fatigue—Sorafenib—liver cancer	0.000525	0.00414	CcSEcCtD
Orlistat—Pain—Sorafenib—liver cancer	0.00052	0.00411	CcSEcCtD
Orlistat—Hepatic failure—Epirubicin—liver cancer	0.000509	0.00402	CcSEcCtD
Orlistat—Eczema—Epirubicin—liver cancer	0.000509	0.00402	CcSEcCtD
Orlistat—Gastrointestinal pain—Sorafenib—liver cancer	0.000497	0.00393	CcSEcCtD
Orlistat—Increased appetite—Epirubicin—liver cancer	0.000487	0.00385	CcSEcCtD
Orlistat—Diabetes mellitus—Doxorubicin—liver cancer	0.000487	0.00384	CcSEcCtD
Orlistat—Menopausal symptoms—Epirubicin—liver cancer	0.000485	0.00383	CcSEcCtD
Orlistat—Urticaria—Sorafenib—liver cancer	0.000483	0.00382	CcSEcCtD
Orlistat—Abdominal pain—Sorafenib—liver cancer	0.000481	0.0038	CcSEcCtD
Orlistat—Body temperature increased—Sorafenib—liver cancer	0.000481	0.0038	CcSEcCtD
Orlistat—Dermatitis bullous—Epirubicin—liver cancer	0.000479	0.00378	CcSEcCtD
Orlistat—Eczema—Doxorubicin—liver cancer	0.000471	0.00372	CcSEcCtD
Orlistat—Hepatic failure—Doxorubicin—liver cancer	0.000471	0.00372	CcSEcCtD
Orlistat—Hypoglycaemia—Epirubicin—liver cancer	0.000469	0.0037	CcSEcCtD
Orlistat—Osteoarthritis—Epirubicin—liver cancer	0.000457	0.00361	CcSEcCtD
Orlistat—Increased appetite—Doxorubicin—liver cancer	0.000451	0.00356	CcSEcCtD
Orlistat—Menopausal symptoms—Doxorubicin—liver cancer	0.000449	0.00354	CcSEcCtD
Orlistat—Hypersensitivity—Sorafenib—liver cancer	0.000448	0.00354	CcSEcCtD
Orlistat—Dermatitis bullous—Doxorubicin—liver cancer	0.000443	0.0035	CcSEcCtD
Orlistat—Asthenia—Sorafenib—liver cancer	0.000436	0.00345	CcSEcCtD
Orlistat—Hypoglycaemia—Doxorubicin—liver cancer	0.000434	0.00343	CcSEcCtD
Orlistat—Pruritus—Sorafenib—liver cancer	0.00043	0.0034	CcSEcCtD
Orlistat—Osteoarthritis—Doxorubicin—liver cancer	0.000423	0.00334	CcSEcCtD
Orlistat—Dry skin—Epirubicin—liver cancer	0.000419	0.00331	CcSEcCtD
Orlistat—Abdominal pain upper—Epirubicin—liver cancer	0.000418	0.0033	CcSEcCtD
Orlistat—Hypokalaemia—Epirubicin—liver cancer	0.000416	0.00329	CcSEcCtD
Orlistat—Diarrhoea—Sorafenib—liver cancer	0.000416	0.00329	CcSEcCtD
Orlistat—Breast disorder—Epirubicin—liver cancer	0.000413	0.00326	CcSEcCtD
Orlistat—Gastritis—Epirubicin—liver cancer	0.000405	0.0032	CcSEcCtD
Orlistat—Dizziness—Sorafenib—liver cancer	0.000402	0.00318	CcSEcCtD
Orlistat—Abdominal distension—Epirubicin—liver cancer	0.000398	0.00314	CcSEcCtD
Orlistat—Asthma—Epirubicin—liver cancer	0.000395	0.00312	CcSEcCtD
Orlistat—Influenza—Epirubicin—liver cancer	0.000395	0.00312	CcSEcCtD
Orlistat—Dry skin—Doxorubicin—liver cancer	0.000388	0.00306	CcSEcCtD
Orlistat—Pancreatitis—Epirubicin—liver cancer	0.000388	0.00306	CcSEcCtD
Orlistat—Vomiting—Sorafenib—liver cancer	0.000387	0.00305	CcSEcCtD
Orlistat—Abdominal pain upper—Doxorubicin—liver cancer	0.000387	0.00305	CcSEcCtD
Orlistat—Hypokalaemia—Doxorubicin—liver cancer	0.000385	0.00304	CcSEcCtD
Orlistat—Rash—Sorafenib—liver cancer	0.000384	0.00303	CcSEcCtD
Orlistat—Dermatitis—Sorafenib—liver cancer	0.000383	0.00303	CcSEcCtD
Orlistat—Breast disorder—Doxorubicin—liver cancer	0.000382	0.00302	CcSEcCtD
Orlistat—Headache—Sorafenib—liver cancer	0.000381	0.00301	CcSEcCtD
Orlistat—Gastritis—Doxorubicin—liver cancer	0.000375	0.00296	CcSEcCtD
Orlistat—Abdominal distension—Doxorubicin—liver cancer	0.000368	0.00291	CcSEcCtD
Orlistat—Upper respiratory tract infection—Epirubicin—liver cancer	0.000367	0.0029	CcSEcCtD
Orlistat—Asthma—Doxorubicin—liver cancer	0.000366	0.00289	CcSEcCtD
Orlistat—Influenza—Doxorubicin—liver cancer	0.000366	0.00289	CcSEcCtD
Orlistat—Nausea—Sorafenib—liver cancer	0.000361	0.00285	CcSEcCtD
Orlistat—Pancreatitis—Doxorubicin—liver cancer	0.000359	0.00283	CcSEcCtD
Orlistat—Infestation—Epirubicin—liver cancer	0.000353	0.00278	CcSEcCtD
Orlistat—Infestation NOS—Epirubicin—liver cancer	0.000353	0.00278	CcSEcCtD
Orlistat—Renal failure—Epirubicin—liver cancer	0.000347	0.00274	CcSEcCtD
Orlistat—Neuropathy peripheral—Epirubicin—liver cancer	0.000346	0.00273	CcSEcCtD
Orlistat—Urinary tract infection—Epirubicin—liver cancer	0.000343	0.00271	CcSEcCtD
Orlistat—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00034	0.00269	CcSEcCtD
Orlistat—Hepatobiliary disease—Epirubicin—liver cancer	0.000333	0.00263	CcSEcCtD
Orlistat—Sinusitis—Epirubicin—liver cancer	0.000331	0.00261	CcSEcCtD
Orlistat—Infestation—Doxorubicin—liver cancer	0.000326	0.00258	CcSEcCtD
Orlistat—Infestation NOS—Doxorubicin—liver cancer	0.000326	0.00258	CcSEcCtD
Orlistat—Renal failure—Doxorubicin—liver cancer	0.000321	0.00253	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—liver cancer	0.00032	0.00253	CcSEcCtD
Orlistat—Haemoglobin—Epirubicin—liver cancer	0.000318	0.00251	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—liver cancer	0.000317	0.0025	CcSEcCtD
Orlistat—Hepatitis—Epirubicin—liver cancer	0.000316	0.0025	CcSEcCtD
Orlistat—Haemorrhage—Epirubicin—liver cancer	0.000316	0.0025	CcSEcCtD
Orlistat—Pharyngitis—Epirubicin—liver cancer	0.000314	0.00248	CcSEcCtD
Orlistat—Urinary tract disorder—Epirubicin—liver cancer	0.000313	0.00247	CcSEcCtD
Orlistat—Oedema peripheral—Epirubicin—liver cancer	0.000312	0.00246	CcSEcCtD
Orlistat—Urethral disorder—Epirubicin—liver cancer	0.00031	0.00245	CcSEcCtD
Orlistat—Hepatobiliary disease—Doxorubicin—liver cancer	0.000308	0.00244	CcSEcCtD
Orlistat—Sinusitis—Doxorubicin—liver cancer	0.000306	0.00242	CcSEcCtD
Orlistat—Haemoglobin—Doxorubicin—liver cancer	0.000294	0.00232	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—liver cancer	0.000293	0.00231	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—liver cancer	0.000293	0.00231	CcSEcCtD
Orlistat—Pharyngitis—Doxorubicin—liver cancer	0.000291	0.0023	CcSEcCtD
Orlistat—Urinary tract disorder—Doxorubicin—liver cancer	0.000289	0.00228	CcSEcCtD
Orlistat—Oedema peripheral—Doxorubicin—liver cancer	0.000288	0.00228	CcSEcCtD
Orlistat—Urethral disorder—Doxorubicin—liver cancer	0.000287	0.00227	CcSEcCtD
Orlistat—Immune system disorder—Epirubicin—liver cancer	0.000286	0.00226	CcSEcCtD
Orlistat—Mediastinal disorder—Epirubicin—liver cancer	0.000285	0.00225	CcSEcCtD
Orlistat—Alopecia—Epirubicin—liver cancer	0.00028	0.00221	CcSEcCtD
Orlistat—Mental disorder—Epirubicin—liver cancer	0.000277	0.00219	CcSEcCtD
Orlistat—Malnutrition—Epirubicin—liver cancer	0.000275	0.00218	CcSEcCtD
Orlistat—Flatulence—Epirubicin—liver cancer	0.000271	0.00214	CcSEcCtD
Orlistat—Dysgeusia—Epirubicin—liver cancer	0.00027	0.00213	CcSEcCtD
Orlistat—Back pain—Epirubicin—liver cancer	0.000266	0.0021	CcSEcCtD
Orlistat—Muscle spasms—Epirubicin—liver cancer	0.000265	0.00209	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—liver cancer	0.000264	0.00209	CcSEcCtD
Orlistat—Mediastinal disorder—Doxorubicin—liver cancer	0.000264	0.00208	CcSEcCtD
Orlistat—Vision blurred—Epirubicin—liver cancer	0.00026	0.00205	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—liver cancer	0.000259	0.00204	CcSEcCtD
Orlistat—Mental disorder—Doxorubicin—liver cancer	0.000257	0.00203	CcSEcCtD
Orlistat—Ill-defined disorder—Epirubicin—liver cancer	0.000256	0.00202	CcSEcCtD
Orlistat—Malnutrition—Doxorubicin—liver cancer	0.000255	0.00201	CcSEcCtD
Orlistat—Flatulence—Doxorubicin—liver cancer	0.000251	0.00198	CcSEcCtD
Orlistat—Dysgeusia—Doxorubicin—liver cancer	0.00025	0.00197	CcSEcCtD
Orlistat—Malaise—Epirubicin—liver cancer	0.000248	0.00196	CcSEcCtD
Orlistat—Vertigo—Epirubicin—liver cancer	0.000248	0.00195	CcSEcCtD
Orlistat—Back pain—Doxorubicin—liver cancer	0.000247	0.00195	CcSEcCtD
Orlistat—Muscle spasms—Doxorubicin—liver cancer	0.000245	0.00194	CcSEcCtD
Orlistat—Palpitations—Epirubicin—liver cancer	0.000243	0.00192	CcSEcCtD
Orlistat—Cough—Epirubicin—liver cancer	0.00024	0.0019	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—liver cancer	0.00024	0.0019	CcSEcCtD
Orlistat—Convulsion—Epirubicin—liver cancer	0.000239	0.00189	CcSEcCtD
Orlistat—Ill-defined disorder—Doxorubicin—liver cancer	0.000237	0.00187	CcSEcCtD
Orlistat—Chest pain—Epirubicin—liver cancer	0.000235	0.00185	CcSEcCtD
Orlistat—Myalgia—Epirubicin—liver cancer	0.000235	0.00185	CcSEcCtD
Orlistat—Anxiety—Epirubicin—liver cancer	0.000234	0.00185	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000233	0.00184	CcSEcCtD
Orlistat—Discomfort—Epirubicin—liver cancer	0.000232	0.00183	CcSEcCtD
Orlistat—Malaise—Doxorubicin—liver cancer	0.00023	0.00182	CcSEcCtD
Orlistat—Dry mouth—Epirubicin—liver cancer	0.000229	0.00181	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—liver cancer	0.000229	0.00181	CcSEcCtD
Orlistat—Palpitations—Doxorubicin—liver cancer	0.000225	0.00178	CcSEcCtD
Orlistat—Oedema—Epirubicin—liver cancer	0.000225	0.00178	CcSEcCtD
Orlistat—Anaphylactic shock—Epirubicin—liver cancer	0.000225	0.00178	CcSEcCtD
Orlistat—Infection—Epirubicin—liver cancer	0.000223	0.00176	CcSEcCtD
Orlistat—Cough—Doxorubicin—liver cancer	0.000222	0.00176	CcSEcCtD
Orlistat—Convulsion—Doxorubicin—liver cancer	0.000221	0.00174	CcSEcCtD
Orlistat—Nervous system disorder—Epirubicin—liver cancer	0.00022	0.00174	CcSEcCtD
Orlistat—Skin disorder—Epirubicin—liver cancer	0.000218	0.00172	CcSEcCtD
Orlistat—Hyperhidrosis—Epirubicin—liver cancer	0.000217	0.00172	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—liver cancer	0.000217	0.00171	CcSEcCtD
Orlistat—Myalgia—Doxorubicin—liver cancer	0.000217	0.00171	CcSEcCtD
Orlistat—Anxiety—Doxorubicin—liver cancer	0.000216	0.00171	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000216	0.0017	CcSEcCtD
Orlistat—Discomfort—Doxorubicin—liver cancer	0.000214	0.00169	CcSEcCtD
Orlistat—Dry mouth—Doxorubicin—liver cancer	0.000212	0.00168	CcSEcCtD
Orlistat—Oedema—Doxorubicin—liver cancer	0.000208	0.00164	CcSEcCtD
Orlistat—Anaphylactic shock—Doxorubicin—liver cancer	0.000208	0.00164	CcSEcCtD
Orlistat—Infection—Doxorubicin—liver cancer	0.000207	0.00163	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000205	0.00162	CcSEcCtD
Orlistat—Nervous system disorder—Doxorubicin—liver cancer	0.000204	0.00161	CcSEcCtD
Orlistat—Insomnia—Epirubicin—liver cancer	0.000203	0.00161	CcSEcCtD
Orlistat—Skin disorder—Doxorubicin—liver cancer	0.000202	0.0016	CcSEcCtD
Orlistat—Paraesthesia—Epirubicin—liver cancer	0.000202	0.00159	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—liver cancer	0.000201	0.00159	CcSEcCtD
Orlistat—Dyspepsia—Epirubicin—liver cancer	0.000198	0.00156	CcSEcCtD
Orlistat—Decreased appetite—Epirubicin—liver cancer	0.000195	0.00154	CcSEcCtD
Orlistat—Gastrointestinal disorder—Epirubicin—liver cancer	0.000194	0.00153	CcSEcCtD
Orlistat—Fatigue—Epirubicin—liver cancer	0.000194	0.00153	CcSEcCtD
Orlistat—Pain—Epirubicin—liver cancer	0.000192	0.00152	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00019	0.0015	CcSEcCtD
Orlistat—Insomnia—Doxorubicin—liver cancer	0.000188	0.00149	CcSEcCtD
Orlistat—Paraesthesia—Doxorubicin—liver cancer	0.000187	0.00148	CcSEcCtD
Orlistat—Feeling abnormal—Epirubicin—liver cancer	0.000185	0.00146	CcSEcCtD
Orlistat—Gastrointestinal pain—Epirubicin—liver cancer	0.000184	0.00145	CcSEcCtD
Orlistat—Dyspepsia—Doxorubicin—liver cancer	0.000183	0.00145	CcSEcCtD
Orlistat—Decreased appetite—Doxorubicin—liver cancer	0.000181	0.00143	CcSEcCtD
Orlistat—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00018	0.00142	CcSEcCtD
Orlistat—Fatigue—Doxorubicin—liver cancer	0.000179	0.00142	CcSEcCtD
Orlistat—Urticaria—Epirubicin—liver cancer	0.000179	0.00141	CcSEcCtD
Orlistat—Pain—Doxorubicin—liver cancer	0.000178	0.0014	CcSEcCtD
Orlistat—Body temperature increased—Epirubicin—liver cancer	0.000178	0.0014	CcSEcCtD
Orlistat—Abdominal pain—Epirubicin—liver cancer	0.000178	0.0014	CcSEcCtD
Orlistat—Feeling abnormal—Doxorubicin—liver cancer	0.000171	0.00135	CcSEcCtD
Orlistat—Gastrointestinal pain—Doxorubicin—liver cancer	0.00017	0.00134	CcSEcCtD
Orlistat—Hypersensitivity—Epirubicin—liver cancer	0.000166	0.00131	CcSEcCtD
Orlistat—Urticaria—Doxorubicin—liver cancer	0.000165	0.00131	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—liver cancer	0.000164	0.0013	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—liver cancer	0.000164	0.0013	CcSEcCtD
Orlistat—Asthenia—Epirubicin—liver cancer	0.000161	0.00127	CcSEcCtD
Orlistat—Pruritus—Epirubicin—liver cancer	0.000159	0.00126	CcSEcCtD
Orlistat—Diarrhoea—Epirubicin—liver cancer	0.000154	0.00121	CcSEcCtD
Orlistat—Hypersensitivity—Doxorubicin—liver cancer	0.000153	0.00121	CcSEcCtD
Orlistat—Asthenia—Doxorubicin—liver cancer	0.000149	0.00118	CcSEcCtD
Orlistat—Dizziness—Epirubicin—liver cancer	0.000149	0.00117	CcSEcCtD
Orlistat—Pruritus—Doxorubicin—liver cancer	0.000147	0.00116	CcSEcCtD
Orlistat—Vomiting—Epirubicin—liver cancer	0.000143	0.00113	CcSEcCtD
Orlistat—Diarrhoea—Doxorubicin—liver cancer	0.000142	0.00112	CcSEcCtD
Orlistat—Rash—Epirubicin—liver cancer	0.000142	0.00112	CcSEcCtD
Orlistat—Dermatitis—Epirubicin—liver cancer	0.000142	0.00112	CcSEcCtD
Orlistat—Headache—Epirubicin—liver cancer	0.000141	0.00111	CcSEcCtD
Orlistat—Dizziness—Doxorubicin—liver cancer	0.000138	0.00109	CcSEcCtD
Orlistat—Nausea—Epirubicin—liver cancer	0.000134	0.00105	CcSEcCtD
Orlistat—Vomiting—Doxorubicin—liver cancer	0.000132	0.00104	CcSEcCtD
Orlistat—Rash—Doxorubicin—liver cancer	0.000131	0.00104	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—liver cancer	0.000131	0.00103	CcSEcCtD
Orlistat—Headache—Doxorubicin—liver cancer	0.00013	0.00103	CcSEcCtD
Orlistat—Nausea—Doxorubicin—liver cancer	0.000124	0.000976	CcSEcCtD
Orlistat—PNLIP—Metabolism—PIK3CB—liver cancer	4.88e-05	0.000241	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	4.86e-05	0.000239	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CRABP1—liver cancer	4.82e-05	0.000238	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CG—liver cancer	4.77e-05	0.000235	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CD—liver cancer	4.73e-05	0.000233	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.72e-05	0.000233	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP2E1—liver cancer	4.7e-05	0.000232	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—HRAS—liver cancer	4.7e-05	0.000232	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—HRAS—liver cancer	4.7e-05	0.000232	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	4.7e-05	0.000232	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CD—liver cancer	4.68e-05	0.000231	CbGpPWpGaD
Orlistat—FASN—Disease—SERPINE1—liver cancer	4.68e-05	0.000231	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	4.64e-05	0.000229	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SERPINE1—liver cancer	4.63e-05	0.000228	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FST—liver cancer	4.62e-05	0.000228	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CDKN1B—liver cancer	4.62e-05	0.000228	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CDKN1B—liver cancer	4.62e-05	0.000228	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AKT1—liver cancer	4.57e-05	0.000225	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AKT1—liver cancer	4.57e-05	0.000225	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CASP3—liver cancer	4.53e-05	0.000223	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CASP3—liver cancer	4.53e-05	0.000223	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL2—liver cancer	4.52e-05	0.000223	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL2—liver cancer	4.52e-05	0.000223	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CG—liver cancer	4.5e-05	0.000222	CbGpPWpGaD
Orlistat—PNLIP—Disease—STAT3—liver cancer	4.5e-05	0.000222	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL6—liver cancer	4.5e-05	0.000222	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL6—liver cancer	4.5e-05	0.000222	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCND1—liver cancer	4.41e-05	0.000217	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TRIO—liver cancer	4.41e-05	0.000217	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCND1—liver cancer	4.41e-05	0.000217	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—JUN—liver cancer	4.4e-05	0.000217	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—JUN—liver cancer	4.4e-05	0.000217	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CTNNB1—liver cancer	4.36e-05	0.000215	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CTNNB1—liver cancer	4.36e-05	0.000215	CbGpPWpGaD
Orlistat—FASN—Metabolism—PPARG—liver cancer	4.35e-05	0.000214	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.34e-05	0.000214	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	4.32e-05	0.000213	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GGT1—liver cancer	4.32e-05	0.000213	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MMP9—liver cancer	4.28e-05	0.000211	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MMP9—liver cancer	4.28e-05	0.000211	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CDKN1A—liver cancer	4.26e-05	0.00021	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CDKN1A—liver cancer	4.26e-05	0.00021	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR4—liver cancer	4.23e-05	0.000208	CbGpPWpGaD
Orlistat—FASN—Disease—RAF1—liver cancer	4.22e-05	0.000208	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HPGDS—liver cancer	4.21e-05	0.000208	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CD—liver cancer	4.19e-05	0.000207	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.19e-05	0.000207	CbGpPWpGaD
Orlistat—PNLIP—Disease—MYC—liver cancer	4.18e-05	0.000206	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RAF1—liver cancer	4.18e-05	0.000206	CbGpPWpGaD
Orlistat—PNLIP—Disease—TGFB1—liver cancer	4.17e-05	0.000206	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MAPK8—liver cancer	4.16e-05	0.000205	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MAPK8—liver cancer	4.16e-05	0.000205	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AKT1—liver cancer	4.15e-05	0.000205	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AKT1—liver cancer	4.15e-05	0.000205	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SERPINE1—liver cancer	4.15e-05	0.000204	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ALB—liver cancer	4.14e-05	0.000204	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CB—liver cancer	4.12e-05	0.000203	CbGpPWpGaD
Orlistat—FASN—Disease—MTOR—liver cancer	4.12e-05	0.000203	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PRKCE—liver cancer	4.12e-05	0.000203	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MTOR—liver cancer	4.08e-05	0.000201	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CB—liver cancer	4.08e-05	0.000201	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	3.97e-05	0.000196	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CD—liver cancer	3.96e-05	0.000195	CbGpPWpGaD
Orlistat—FASN—Metabolism—ALB—liver cancer	3.91e-05	0.000193	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTP1—liver cancer	3.88e-05	0.000191	CbGpPWpGaD
Orlistat—FASN—Disease—CDKN1B—liver cancer	3.87e-05	0.000191	CbGpPWpGaD
Orlistat—PNLIP—Disease—KRAS—liver cancer	3.86e-05	0.000191	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—liver cancer	3.84e-05	0.000189	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—liver cancer	3.84e-05	0.000189	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CDKN1B—liver cancer	3.83e-05	0.000189	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	3.83e-05	0.000189	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	3.82e-05	0.000188	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—STAT3—liver cancer	3.8e-05	0.000188	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—STAT3—liver cancer	3.8e-05	0.000188	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—liver cancer	3.77e-05	0.000186	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PSMA4—liver cancer	3.76e-05	0.000185	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PSMD10—liver cancer	3.76e-05	0.000185	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CASP3—liver cancer	3.75e-05	0.000185	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL2—liver cancer	3.75e-05	0.000185	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—RAF1—liver cancer	3.74e-05	0.000184	CbGpPWpGaD
Orlistat—FASN—Disease—CTNNB1—liver cancer	3.65e-05	0.00018	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GOT2—liver cancer	3.65e-05	0.00018	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CB—liver cancer	3.65e-05	0.00018	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCND1—liver cancer	3.65e-05	0.00018	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—JUN—liver cancer	3.64e-05	0.00018	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CSF2—liver cancer	3.64e-05	0.00018	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CTNNB1—liver cancer	3.62e-05	0.000178	CbGpPWpGaD
Orlistat—FASN—Disease—CDKN1A—liver cancer	3.57e-05	0.000176	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTM1—liver cancer	3.56e-05	0.000176	CbGpPWpGaD
Orlistat—PNLIP—Disease—PIK3CA—liver cancer	3.55e-05	0.000175	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MMP9—liver cancer	3.55e-05	0.000175	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MYC—liver cancer	3.53e-05	0.000174	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MYC—liver cancer	3.53e-05	0.000174	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CDKN1A—liver cancer	3.53e-05	0.000174	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—liver cancer	3.53e-05	0.000174	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TGFB1—liver cancer	3.53e-05	0.000174	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TGFB1—liver cancer	3.53e-05	0.000174	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	3.52e-05	0.000173	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CB—liver cancer	3.45e-05	0.00017	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MAPK8—liver cancer	3.45e-05	0.00017	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP2E1—liver cancer	3.43e-05	0.000169	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP1A1—liver cancer	3.38e-05	0.000167	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL2—liver cancer	3.35e-05	0.000165	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADAM17—liver cancer	3.34e-05	0.000165	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	3.33e-05	0.000164	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.33e-05	0.000164	CbGpPWpGaD
Orlistat—PNLIP—Disease—HRAS—liver cancer	3.29e-05	0.000162	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KRAS—liver cancer	3.27e-05	0.000161	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KRAS—liver cancer	3.27e-05	0.000161	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYCS—liver cancer	3.21e-05	0.000158	CbGpPWpGaD
Orlistat—FASN—Disease—STAT3—liver cancer	3.18e-05	0.000157	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—liver cancer	3.18e-05	0.000157	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GOT1—liver cancer	3.15e-05	0.000155	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GGT1—liver cancer	3.15e-05	0.000155	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—STAT3—liver cancer	3.15e-05	0.000155	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—liver cancer	3.14e-05	0.000155	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PSMD10—liver cancer	3.14e-05	0.000155	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PSMA4—liver cancer	3.14e-05	0.000155	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PIK3CA—liver cancer	3e-05	0.000148	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PIK3CA—liver cancer	3e-05	0.000148	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CA—liver cancer	2.97e-05	0.000147	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—liver cancer	2.96e-05	0.000146	CbGpPWpGaD
Orlistat—FASN—Disease—TGFB1—liver cancer	2.95e-05	0.000146	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—liver cancer	2.93e-05	0.000144	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TGFB1—liver cancer	2.92e-05	0.000144	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—liver cancer	2.9e-05	0.000143	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—liver cancer	2.9e-05	0.000143	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—liver cancer	2.9e-05	0.000143	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—F2—liver cancer	2.86e-05	0.000141	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—liver cancer	2.85e-05	0.000141	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTP1—liver cancer	2.83e-05	0.00014	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HMOX1—liver cancer	2.79e-05	0.000138	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HRAS—liver cancer	2.78e-05	0.000137	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HRAS—liver cancer	2.78e-05	0.000137	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CG—liver cancer	2.74e-05	0.000135	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—liver cancer	2.73e-05	0.000135	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—liver cancer	2.71e-05	0.000133	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—liver cancer	2.66e-05	0.000131	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—liver cancer	2.66e-05	0.000131	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TGFB1—liver cancer	2.62e-05	0.000129	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTM1—liver cancer	2.6e-05	0.000128	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—UGDH—liver cancer	2.53e-05	0.000125	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CA—liver cancer	2.51e-05	0.000124	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CA—liver cancer	2.49e-05	0.000123	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP1A1—liver cancer	2.47e-05	0.000122	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—liver cancer	2.45e-05	0.000121	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—liver cancer	2.45e-05	0.000121	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PRKCE—liver cancer	2.43e-05	0.00012	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—liver cancer	2.43e-05	0.00012	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—liver cancer	2.42e-05	0.00012	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—liver cancer	2.41e-05	0.000119	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CD—liver cancer	2.41e-05	0.000119	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—EPT1—liver cancer	2.38e-05	0.000117	CbGpPWpGaD
Orlistat—FASN—Disease—HRAS—liver cancer	2.32e-05	0.000115	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF2—liver cancer	2.3e-05	0.000114	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MTHFR—liver cancer	2.3e-05	0.000113	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HRAS—liver cancer	2.3e-05	0.000113	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARA—liver cancer	2.26e-05	0.000111	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TAT—liver cancer	2.25e-05	0.000111	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CA—liver cancer	2.23e-05	0.00011	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—liver cancer	2.22e-05	0.00011	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—liver cancer	2.2e-05	0.000109	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—liver cancer	2.15e-05	0.000106	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CSF2—liver cancer	2.15e-05	0.000106	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—RAF1—liver cancer	2.15e-05	0.000106	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—H2AFX—liver cancer	2.12e-05	0.000105	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CA—liver cancer	2.1e-05	0.000104	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CB—liver cancer	2.1e-05	0.000103	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HRAS—liver cancer	2.06e-05	0.000102	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—liver cancer	2.05e-05	0.000101	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—liver cancer	2.03e-05	0.0001	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.03e-05	0.0001	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CG—liver cancer	1.93e-05	9.53e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2—liver cancer	1.93e-05	9.49e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TERT—liver cancer	1.92e-05	9.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARG—liver cancer	1.87e-05	9.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—liver cancer	1.82e-05	8.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KDR—liver cancer	1.75e-05	8.65e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK14—liver cancer	1.74e-05	8.59e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—liver cancer	1.72e-05	8.47e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ESR1—liver cancer	1.71e-05	8.43e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CD—liver cancer	1.7e-05	8.38e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—F2—liver cancer	1.69e-05	8.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALB—liver cancer	1.68e-05	8.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APC—liver cancer	1.62e-05	7.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CG—liver cancer	1.62e-05	7.97e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GLUL—liver cancer	1.53e-05	7.55e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CPT1B—liver cancer	1.53e-05	7.55e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BRAF—liver cancer	1.52e-05	7.49e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CB—liver cancer	1.48e-05	7.3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NR1H4—liver cancer	1.48e-05	7.28e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA3—liver cancer	1.45e-05	7.16e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CD—liver cancer	1.42e-05	7.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SERPINE1—liver cancer	1.41e-05	6.93e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—liver cancer	1.39e-05	6.86e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA4—liver cancer	1.33e-05	6.55e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA2—liver cancer	1.29e-05	6.38e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CA—liver cancer	1.28e-05	6.3e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RAF1—liver cancer	1.27e-05	6.25e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA1—liver cancer	1.25e-05	6.15e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MTOR—liver cancer	1.24e-05	6.11e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CB—liver cancer	1.24e-05	6.11e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NAT2—liver cancer	1.23e-05	6.09e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALDOB—liver cancer	1.18e-05	5.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HRAS—liver cancer	1.18e-05	5.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1B—liver cancer	1.16e-05	5.73e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP3—liver cancer	1.14e-05	5.62e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2—liver cancer	1.14e-05	5.61e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—liver cancer	1.13e-05	5.58e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CRABP1—liver cancer	1.13e-05	5.57e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCND1—liver cancer	1.11e-05	5.47e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JUN—liver cancer	1.11e-05	5.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CTNNB1—liver cancer	1.1e-05	5.41e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—liver cancer	1.08e-05	5.31e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1A—liver cancer	1.07e-05	5.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK8—liver cancer	1.05e-05	5.16e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—liver cancer	1.04e-05	5.15e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HPGDS—liver cancer	9.87e-06	4.87e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—liver cancer	9.67e-06	4.77e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT3—liver cancer	9.57e-06	4.72e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CA—liver cancer	9.03e-06	4.45e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—liver cancer	8.89e-06	4.38e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFB1—liver cancer	8.87e-06	4.37e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PSMD10—liver cancer	8.8e-06	4.34e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PSMA4—liver cancer	8.8e-06	4.34e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GOT2—liver cancer	8.56e-06	4.22e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—liver cancer	8.22e-06	4.05e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2E1—liver cancer	8.04e-06	3.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CA—liver cancer	7.55e-06	3.72e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYCS—liver cancer	7.53e-06	3.71e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GGT1—liver cancer	7.39e-06	3.64e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GOT1—liver cancer	7.39e-06	3.64e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—liver cancer	7.38e-06	3.64e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—liver cancer	7.3e-06	3.6e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRAS—liver cancer	6.98e-06	3.44e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—liver cancer	6.69e-06	3.3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTP1—liver cancer	6.63e-06	3.27e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HMOX1—liver cancer	6.54e-06	3.23e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—liver cancer	6.17e-06	3.04e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTM1—liver cancer	6.1e-06	3.01e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP1A1—liver cancer	5.78e-06	2.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTHFR—liver cancer	5.39e-06	2.66e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARA—liver cancer	5.29e-06	2.61e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CG—liver cancer	4.53e-06	2.23e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARG—liver cancer	4.37e-06	2.15e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CD—liver cancer	3.98e-06	1.96e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALB—liver cancer	3.93e-06	1.94e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CB—liver cancer	3.47e-06	1.71e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CA—liver cancer	2.11e-06	1.04e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—liver cancer	1.73e-06	8.52e-06	CbGpPWpGaD
